Skip to main content

Grafa News and Videos — Page 1219

Latest

Grafa

European regulators accept Teva and Medincell’s application for long-acting Schizophrenia injection

Teva Pharmaceutical Industries (NYSE:TEVA) and Medincell announced Thursday that the European Medicines Agency has accepted their Marketing Authorization Application for TEV-749, an investigational long-acting injectable formulation designed to treat adults living with schizophrenia.

Read more: European regulators accept Teva and Medincell’s application for long-acting Schizophrenia injection

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift